Fiduciary Management Inc. WI Sells 495,419 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Posted by George Bondi on Jun 7th, 2026

Fiduciary Management Inc. WI reduced its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report) by 9.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,961,969 shares of the company’s stock after selling 495,419 shares during the quarter. Fiduciary Management Inc. WI’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $118,194,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Hantz Financial Services Inc. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after buying an additional 699 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 4.0% during the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock valued at $447,000 after buying an additional 726 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after buying an additional 896 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the last quarter. Finally, Cerity Partners LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 3.1% during the second quarter. Cerity Partners LLC now owns 41,126 shares of the company’s stock valued at $1,175,000 after buying an additional 1,223 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $22.03 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $29.07. The company has a 50-day simple moving average of $22.23 and a two-hundred day simple moving average of $22.87. The firm has a market capitalization of $11.90 billion, a PE ratio of 11.59, a price-to-earnings-growth ratio of 3.97 and a beta of 0.80.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 EPS for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%. The business had revenue of $5.34 billion during the quarter. On average, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Monday, June 8th. Shareholders of record on Friday, May 22nd will be issued a $0.8716 dividend. This represents a yield of 402.0%. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date is Friday, May 22nd. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is 32.11%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Finally, Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, April 24th. Four investment analysts have rated the stock with a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Strong Sell” and a consensus target price of $28.00.

Read Our Latest Report on Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA Company Profile

(Free Report)

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.